Compare ALLO & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLO | QSI |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 273.7M |
| IPO Year | 2018 | N/A |
| Metric | ALLO | QSI |
|---|---|---|
| Price | $1.63 | $1.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $8.27 | $2.63 |
| AVG Volume (30 Days) | 4.2M | ★ 5.4M |
| Earning Date | 11-06-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,177,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $159.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 40.20 |
| 52 Week Low | $0.86 | $0.95 |
| 52 Week High | $3.78 | $3.10 |
| Indicator | ALLO | QSI |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 48.96 |
| Support Level | $1.62 | $1.18 |
| Resistance Level | $1.88 | $1.32 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 56.41 | 72.22 |
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.